Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Family Medicine
Disease Category: Diabetes Mellitus, Type 2
Location: United States, CA
Can you tell me about the study drug?
The Investigational drug being evaluated in the Harmony program is called albiglutide. This novel medication comes from a new class of drugs, which are similar to some types of currently approved diabetes drugs. However, albiglutide is designed to have a much longer-lasting effect.
Whereas some current diabetes medications must be administered multiple time a day by injection, researchers are expecting that one weekly injection albiglutide will prove to be effective in helping control type 2 diabetes.
All study participants receiving treatment with albiglutide will be given an injector pen. The study staff will instruct you on how to use this pen at home to administer your injections.
Why conduct medical research studies?
Medications must be carefully tested through medical research studies to demonstrate their safety and effectiveness before pharmaceutical companies are allowed to sell them to the public. Companies can tehn apply to regulatory agencies for approval to market these drugs to the public.
The researchers conducting this study are required to follow a detailed plan called a protocol, which explains all study procedures. This protocol is approved by an independent board and is designed to protect the safety of all study volunteers. Additionally, researchers must provide potentioal participants with complete answers to any questions they have about the study.
Medical research studies are necessary to test and, ultimately, develop new treatments for a wide variety of medical conditions. Your participation in the Harmony program may help researchers find a way to better control type 2 diabetes. However, your participation is completely voluntary, and you may leave the study at any time, for any reason.
Diablo Clinical Research
2255 Ygnacio Valley Rd., Suite M
Walnut Creek, CA 94598
Research Center Information: Diablo Clinical Research
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these